INTRODUCTION Contributed by: Nadia de la Houssaye, Jones Walker LLP
information can be used in AI development and deployment. Countries with emerging digital health initiatives must balance the potential benefits of AI innovation against the imperative to protect patient privacy and maintain public trust in healthcare sys - tems. The secondary use of healthcare data for AI training presents particular challenges. Clinical data originally collected for patient care purposes requires careful consideration of consent frameworks, de-identifica - tion standards and cross-border transfer restrictions when repurposed for AI development. Synthetic data generation and federated learning approaches offer promising solutions, but these technologies them - selves raise novel legal and technical questions that The global healthcare AI community increasingly rec - ognises that algorithmic bias represents one of the most significant ethical and legal challenges facing the field. Training datasets that inadequately repre - sent diverse patient populations can perpetuate or exacerbate existing healthcare disparities, potentially undermining the very goals that AI seeks to achieve. This concern transcends geographic boundaries, as healthcare inequities exist in virtually every healthcare system worldwide. The challenge is particularly acute in global contexts where AI systems developed in one region may be deployed in populations with significantly different demographic, genetic or socioeconomic character - istics. An AI diagnostic tool trained primarily on data from European or North American populations may perform poorly when applied to patients in sub-Saha - ran Africa or Southeast Asia. This creates both tech - nical challenges related to algorithm generalisability and ethical obligations to ensure that AI innovation benefits all populations equitably. regulatory frameworks must address. Algorithmic Bias and Health Equity Regulatory responses to algorithmic bias vary sig - nificantly across jurisdictions. Some countries are developing specific requirements for bias testing and mitigation, while others rely on broader anti-discrim - ination frameworks. Healthcare AI developers must increasingly implement systematic approaches to bias
detection and remediation that can meet varying inter - national standards while advancing the broader goals of health equity. Professional Liability in the Age of AI The integration of AI into clinical practice raises novel questions about professional liability and standards of care that legal systems worldwide are struggling to address. Traditional medical malpractice frameworks assume human decision-making processes that may not adequately account for algorithm-assisted care. When AI systems provide diagnostic recommenda - tions or treatment suggestions, determining liability for adverse outcomes becomes complex, particularly when multiple stakeholders – including healthcare providers, AI developers and healthcare institutions – may share responsibility. Different legal systems approach these challenges in varying ways. Common-law jurisdictions may rely on evolving case law to establish standards for AI- assisted care, while civil-law systems may require more explicit legislative or regulatory guidance. Pro - fessional medical organisations across the globe are developing guidelines for responsible AI use, but these standards are not uniform and may not have the force of law. Healthcare providers worldwide must increasingly document their interactions with AI systems, demon - strating appropriate clinical judgment in accepting, modifying or rejecting algorithmic recommendations. This documentation burden varies across jurisdictions but represents a common challenge as healthcare AI adoption accelerates globally. Market Dynamics and Innovation Ecosystems The global healthcare AI market reflects broader pat - terns of technological innovation and investment, with significant activity concentrated in major technology hubs while emerging markets present both opportu - nities and challenges. North American and European companies continue to lead in healthcare AI develop - ment, supported by robust venture capital ecosys - tems and sophisticated regulatory frameworks. Asian markets, particularly China, Japan and Singapore, are rapidly emerging as significant players with substan - tial government support for AI innovation.
6
CHAMBERS.COM
Powered by FlippingBook